VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced a significant milestone in its oncology pipeline. The company's VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development, following the successful completion of the discovery portion of its collaboration with OmniAb Inc. This progress highlights VERAXA's continued momentum in developing innovative treatments for difficult-to-treat cancers.
The collaboration with OmniAb, which began in May 2025, has delivered a portfolio of therapeutic antibody binders. With the discovery work completed, VERAXA will now focus on engineering the final bispecific ADC candidate by combining these binders with its proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's core expertise and represents one of its more advanced development programs.
In parallel with the VXA-222 advancement, VERAXA has expanded its intellectual property portfolio. The company recently filed its first patent applications related to its BiTAC platform, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. VERAXA now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, securing the company's innovative technologies for years to come.
VERAXA continues to build a diversified oncology pipeline that spans bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats. This strategic approach aims to address a range of challenging cancers, positioning the company for long-term growth in the competitive oncology market.
The announcement comes at a time when the biotech industry is increasingly focused on next-generation antibody technologies. Bispecific ADCs, which combine the targeting capabilities of antibodies with the potent cell-killing effects of cytotoxic drugs, are seen as a promising avenue for improving cancer treatment outcomes. VERAXA's progress in this area, coupled with its robust IP strategy, could provide a competitive edge in the rapidly evolving landscape.
Investors and industry observers will be watching VERAXA's next steps as it advances VXA-222 through preclinical validation. The company's ability to deliver on its development milestones and expand its patent portfolio will be key indicators of its potential to bring innovative therapies to market.
